Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125358861 | 12535886 | 1 | I | 20160627 | 20160707 | 20160707 | PER | US-ELI_LILLY_AND_COMPANY-US201606009950 | ELI LILLY AND CO | 72.00 | YR | F | Y | 0.00000 | 20160707 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125358861 | 12535886 | 1 | PS | ADCIRCA | TADALAFIL | 1 | Unknown | UNK, UNKNOWN | U | U | 21368 | TABLET | |||||||
| 125358861 | 12535886 | 2 | SS | AMBRISENTAN | AMBRISENTAN | 1 | Unknown | 10 MG, QD | 1504768A | 0 | 10 | MG | QD | ||||||
| 125358861 | 12535886 | 3 | C | ADEMPAS | RIOCIGUAT | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125358861 | 12535886 | 1 | Product used for unknown indication |
| 125358861 | 12535886 | 2 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125358861 | 12535886 | Erythema | |
| 125358861 | 12535886 | Fluid retention | |
| 125358861 | 12535886 | Sinus disorder | |
| 125358861 | 12535886 | Skin disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |